Journal of ethnopharmacology
February 10, 2024
Tiago Arruda Sanchez, Lucas Rego Ramos, Felipe Araujo et al.
12 citations
Ayahuasca, a traditional Amazonian beverage, attenuates brain activity in the amygdala—a region central to fear processing—when people view aversive (fearful or disgusted) faces, while enhancing activation in the insular cortex and right dorsolateral prefrontal cortex. Nineteen experienced male users underwent fMRI before and 50 minutes after ingesting ayahuasca. Self-reported anxiety and mental sedation also decreased. The findings suggest ayahuasca may promote emotion regulation in response to negative stimuli, with corresponding improvements in cognition.
Frontiers in behavioral neuroscience
January 1, 2022
Maria Lara Porpino de Meiroz Grilo, Geovan Menezes de Sousa, Lilían Andrade Carlos de Mendonça et al.
12 citations
Repeated ayahuasca administration before and during social isolation prevented depressive-like behaviors and cortisol alterations in common marmosets. Animals given ayahuasca showed higher cortisol reactivity and fecal cortisol levels similar to family-group controls, no signs of anhedonia, and no increase in chronic stress-related behaviors, unlike isolated animals that received no intervention. The findings suggest ayahuasca promotes resilient responses and may have a prophylactic action against depression.
Nature communications
August 13, 2025
William Wong, Rubén Herzog, Kátia Cristine Andrade et al.
10 citations
A new open database, the DREAM database, combines standardized sleep magneto/electroencephalography (M/EEG) recordings with dream reports from 505 participants across 20 datasets, totaling 2,643 awakenings. Each awakening includes at least 20 seconds of high-resolution sleep EEG (≥100 Hz, ≥2 electrodes) and a classification of the sleeper's reported experience. Analyses showed that reports of conscious experiences during sleep can be predicted from objective EEG features in both REM and NREM sleep. The database aims to overcome limitations of small sample sizes and methodological variability in dream research, enabling larger-scale investigations of the neurocognitive basis of dreaming.
Journal of psychiatric research
August 1, 2024
Eduardo Igor Torquato Cardoso Lopes, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes et al.
9 citations
Subcutaneous esketamine injections given weekly for eight weeks produced a rapid and lasting reduction in suicidality among 18 adults with treatment-resistant depression. Suicidal thoughts dropped within 24 hours after the first dose and remained low throughout the eight-week treatment period. At six months after treatment ended, suicidality was still consistently lower. Clinician ratings showed significant improvement only after two sessions, and 61% of patients achieved remission from suicidal ideation. The findings suggest that weekly subcutaneous esketamine may be a cost-effective way to achieve fast and sustained anti-suicide effects, but controlled studies are needed to confirm these initial observations.
European archives of psychiatry and clinical neuroscience
October 28, 2024
Kaike Thiê da Costa Gonçalves, Vagner Deuel O de Tavares, Maria Luiza de Morais Barros et al.
5 citations
A systematic review of 29 studies examined whether the psychoactive effects of ketamine are linked to its therapeutic benefits for psychiatric disorders. About half of the studies (51.72%) found a positive relationship between ketamine-induced altered states of consciousness and clinical outcomes, while 44.83% found no link, and one study found a negative association. For mood disorders like major depressive disorder and bipolar disorder, 48% of studies showed a positive relationship and 48% showed none. All three studies on substance use disorder reported a positive correlation. The authors conclude the relationship remains uncertain due to high variability across studies.
Journal of clinical psychopharmacology
Vagner Deuel de O Tavares, Kaike Thiê da Costa Gonçalves, Maria Luiza de Morais Barros et al.
1 citation
A meta-analysis of eleven studies found no significant correlation between the psychoactive (psychomimetic) effects of ketamine and clinical outcomes in mental illness, including depression. The overall correlation was r = 0.06, and for depression specifically r = 0.03, both non-significant. Sub-analyses accounting for patient disorders, intravenous administration, assessment instruments, and timing also yielded no significant findings. High heterogeneity was present. The analysis suggests that altered states of consciousness during ketamine sessions are not directly linked to clinical outcomes, but the limited number of studies and heterogeneity make this conclusion preliminary.
medRxiv Preprint Server
May 31, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
preprint
Ketamine rapidly reduces depression symptoms in treatment-resistant depression, but its effects may be enhanced by combining it with psychotherapy. The drug induces neuroplasticity and psychological openness, which could help patients process emotions, restructure thoughts, and maintain improvements. However, research has not yet thoroughly examined whether adding structured psychotherapy to ketamine treatment provides additional benefits.